Statements (54)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:pharmaceuticals
|
| gptkbp:administered_by |
oral tablet
|
| gptkbp:approves |
gptkb:2019
gptkb:FDA |
| gptkbp:casnumber |
1262020-88-0
|
| gptkbp:chemical_formula |
C22 H24 Cl N5 O2 S
|
| gptkbp:clinical_trial |
Phase 1
Phase 2 |
| gptkbp:contraindication |
hypersensitivity to the drug
severe liver impairment |
| gptkbp:developed_by |
gptkb:Genentech
|
| gptkbp:drug_interactions |
CYP3 A4 inducers
CYP3 A4 inhibitors |
| gptkbp:financial_support |
do not crush or chew tablets
take with or without food |
| gptkbp:formulation |
film-coated tablet
|
| https://www.w3.org/2000/01/rdf-schema#label |
Entrectinib
|
| gptkbp:indication |
gptkb:Oncology
gptkb:neuroblastoma solid tumors metastatic breast cancer |
| gptkbp:is_monitored_by |
electrolytes
liver function tests complete blood count |
| gptkbp:marketed_as |
Rozlytrek
|
| gptkbp:mechanism_of_action |
inhibitor of tyrosine kinases
|
| gptkbp:pharmacokinetics |
oral bioavailability
half-life of approximately 22 hours |
| gptkbp:related_products |
gptkb:Brigatinib
gptkb:Alectinib gptkb:Larotrectinib gptkb:Crizotinib gptkb:Entrectinib |
| gptkbp:research_areas |
oncology
targeted therapy precision medicine molecularly targeted drugs |
| gptkbp:side_effect |
dizziness
fatigue nausea diarrhea constipation peripheral edema increased liver enzymes |
| gptkbp:storage |
store at room temperature
protect from moisture |
| gptkbp:strength |
100 mg
200 mg |
| gptkbp:targets |
gptkb:NTRK_gene_fusions
ROS1 gene fusions ALK gene fusions |
| gptkbp:used_for |
treatment of cancer
|
| gptkbp:bfsParent |
gptkb:EMD_Serono
|
| gptkbp:bfsLayer |
5
|